http://www.antigenics.com
http://finance.yahoo.com/q/h?s=AGEN
http://www.form4oracle.com/company?cik=0001098972&ticker=agen
Antigenics, Inc., a biotechnology company, develops treatments for cancers and infectious diseases. It offers Oncophage, a personalized therapeutic cancer vaccine candidate, which is in Phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma. The company�s products also include Aroplatin, a liposomal chemotherapeutic, which is in Phase I clinical trial for the treatment of solid tumors and non-Hodgkin�s lymphoma; AG-707, a therapeutic vaccine program that is in Phase I clinical trial for the treatment of genital herpes; and QS-21, an adjuvant used in various vaccines, including hepatitis, lyme diseases, human immunodeficiency virus, influenza, cancer, Alzheimer�s disease, and malaria. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York, New York.
